Previous Article | Next Article 
Journal of Bacteriology, September 1999, p. 5455-5460, Vol. 181, No. 17
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
ZmaR, a Novel and Widespread Antibiotic Resistance
Determinant That Acetylates Zwittermicin A
Elizabeth A.
Stohl,1,2,
Sean F.
Brady,3
Jon
Clardy,3 and
Jo
Handelsman1,2,*
Department of Plant
Pathology1 and Program in Cellular and
Molecular Biology,2 University of Wisconsin,
Madison, Wisconsin 53706, and Department of Chemistry and
Chemical Biology, Baker Labs, Cornell University, Ithaca, New York
14853-13013
Received 16 March 1999/Accepted 3 June 1999
 |
ABSTRACT |
ZmaR is a resistance determinant of unusual abundance in the
environment and confers on gram-positive and gram-negative bacteria resistance to zwittermicin A, a novel broad-spectrum antibiotic produced by species of Bacillus. The ZmaR protein has no
sequence similarity to proteins of known function; thus, the purpose of the present study was to determine the function of ZmaR in vitro. Cell
extracts of E. coli containing zmaR inactivated
zwittermicin A by covalent modification. Chemical analysis of
inactivated zwittermicin A by 1H NMR, 13C NMR,
and high- and low-resolution mass spectrometry demonstrated that the
inactivated zwittermicin A was acetylated. Purified ZmaR protein
inactivated zwittermicin A, and biochemical assays for acetyltransferase activity with [14C]acetyl coenzyme A
demonstrated that ZmaR catalyzes the acetylation of zwittermicin A with
acetyl coenzyme A as a donor group, suggesting that ZmaR may constitute
a new class of acetyltransferases. Our results allow us to assign a
biochemical function to a resistance protein that has no sequence
similarity to proteins of known function, contributing fundamental
knowledge to the fields of antibiotic resistance and protein function.
 |
INTRODUCTION |
The rise in resistance to
antibiotics threatens their effectiveness in agriculture and medicine.
The development of resistance is driven by both the frequency of
resistance determinants in a given environment and selection by the
antibiotics. Therefore, the current challenge is to understand the
complex interplay of ecological and genetic factors that dictate the
appearance and spread of resistance in pathogens of plants and animals.
Although soil has long been recognized as a rich source of antibiotics, it has not been the focus of study as a source of resistance
determinants. Soil may provide insight into the ecology of resistance
for three reasons. First, antibiotic-producing organisms themselves may be a key source of resistance genes (2, 7), and the soil is
populated with producers of many antibiotics in use in agriculture and
medicine. Second, soil is the most microbiologically rich environment
on earth (36), providing both dense populations and
tremendous genetic diversity. Furthermore, transfer of resistance determinants across wide phylogenetic distances is common in nature generally (26), but it may be more likely to be detected in soil microbes because of the presence of antibiotic producers, which
may provide selection pressure, the large population sizes, and the
physical proximity of highly divergent species.
Of the culturable microbes from soil, Bacillus spp. are
among the most abundant. A recent study showed that approximately one-half of 16S rRNA clones from a grassland soil environment were
Bacillus spp. (8). In a survey of soils from
several continents (32), B. cereus was routinely
found at levels of 105 CFU/g of soil (30a). We
previously identified a zwittermicin A self-resistance gene,
zmaR, from B. cereus UW85, which is functional in
both gram-negative and gram-positive bacteria (19).
zmaR is ubiquitous in soil: approximately 25% of soil
isolates of B. cereus contain zmaR and produce
zwittermicin A (24, 32), indicating that there may be 25,000 copies of zmaR in every gram of soil. Additionally, certain
strains of the insecticidal toxin-producing species of B. thuringiensis, which is the most widely used biopesticide in the
world, carry zmaR and produce zwittermicin A (24,
32). The zwittermicin A exposure from naturally occurring
zwittermicin A production by B. cereus soil isolates and
from the heavy use of zwittermicin A-producing B. thuringiensis in insect control may provide strong selection
pressure for acquisition of zwittermicin A resistance, potentially
zmaR, in soil-dwelling microorganisms. This is particularly
troubling since strains of B. cereus are currently being
developed for use as biological control agents to suppress several
plant diseases caused by the pathogenic Phytophthora and
Pythium oomycetes (11, 22).
Zwittermicin A is a novel antibiotic that does not belong to any
previously described class of antibiotics (13, 29). It is a
linear aminopolyol that has a broad target range, inhibiting many
eukaryotes and prokaryotes, particularly certain plant pathogenic oomycetes belonging to the genera Phytophthora and
Pythium (30). Zwittermicin A contributes to the
ability of B. cereus to suppress certain plant diseases and
acts synergistically with Bt toxin to enhance the insecticidal activity
of B. thuringiensis (4a, 18). Spontaneous
zwittermicin A-resistant mutants of Escherichia coli are
affected in genes encoding subunits of RNA polymerase; however,
zwittermicin A does not appear to inhibit RNA transcription in vivo,
suggesting that zwittermicin A has an unusual mode of action
(31). Therefore, investigation of zwittermicin A resistance in a producing organism will help us predict mechanisms of resistance that may develop in target pathogens and begin designing strategies to
slow the development of resistance, will add to the understanding of
this novel antibiotic, and may aid in determining the mode of action of
zwittermicin A.
zmaR encodes a 43.5-kDa protein with no sequence similarity
to proteins of known function. Recent genome sequencing efforts for
many bacteria (3, 16) have revealed that approximately 40%
of open reading frames are completely uncharacterized. Since modern
biochemical characterization of proteins relies heavily on the
predicted amino acid coding sequence having sequence similarity to
proteins of known function, this represents an immense gap in our
understanding of fundamental biological processes that can only be
filled by assigning functions to these proteins. One of the goals of
this work was to assign a function to ZmaR, a protein with no homology
to proteins of known function. In this work we show that ZmaR
inactivates zwittermicin A by acetylation, suggesting that ZmaR
constitutes a novel acetyltransferase that is abundant in the soil environment.
 |
MATERIALS AND METHODS |
Bacterial strains, plasmids, and culture conditions.
E.
coli DH5
(10), DH5
F'IQ (Stratagene, La Jolla,
Calif.), and BL21(DE3) (Stratagene) were grown on Luria-Bertani (LB) broth or agar unless otherwise indicated (27).
Mueller-Hinton agar was prepared to either full strength (100MH8.1) or
to one-tenth the strength (10MH8.1) as directed by the manufacturer
(Difco Laboratories, Detroit, Mich.) with 40 mM Tris and 40 mM
3-(morpholino)propanesulfonic acid (MOPS) buffers added, and the pH
adjusted to 8.1 with 5 N NaOH. Plate media contained 15 g of agar
per liter, and soft agar contained 7 g of agar per liter.
Antibiotics were added as follows: ampicillin at 50 mg/liter and
kanamycin at 10 mg/liter. Plasmids pGEM-3Zf(+) (Promega, Madison, Wis.)
and pZMG4 (19), pGEM containing zmaR, were used
in cell extract experiments. pCAL-n-EK (Stratagene), a protein
overexpression vector, was used to make pCAL-ZmaR for the
overexpression of the ZmaR protein.
DNA manipulations and analysis.
Plasmid DNA was purified
from E. coli by using the Qiagen plasmid isolation kit
(Qiagen, Chatsworth, Calif.). Plasmid DNA was introduced into E. coli by calcium chloride transformation (27).
Sequencing reactions were performed with the AmpliTaq dye-terminator
Cycle Sequencing kit (Perkin-Elmer Corp., Foster City, Calif.) with
primers 11114 and 11115; primer 11346 (5'-GGTTGTCGAGGAACAATTGC-3'; nucleotide sequence 362 to 381); and primers 1721, 1720, 1641, 1737 (19), and 677 (24). Partial DNA sequences
were aligned and compiled with SeqMan and EditSeq software (DNASTAR
Inc., Madison, Wis.). Primer synthesis and sequencing were done at the
University of Wisconsin Biotechnology Center (Madison, Wis.).
Sequencing was conducted on an ABI model 373A automated DNA sequencer.
Protein comparison searches were conducted by using the BLAST algorithm (1) via the NCBI BLAST electronic mail server.
Preparation of cell-free extracts.
E. coli DH5
F'IQ
carrying plasmid pZMG4 or pGEM (Promega) was grown to an optical
density at 600 nm of 0.5 to 0.6 in LB broth supplemented with
ampicillin and kanamycin (50 and 10 mg/liter, respectively) at 37°C.
Isopropyl-
-D-thiogalactopyranoside (IPTG) was added to a
final concentration of 1 mM to induce expression of genes under control
of the lac promoter, and the culture was allowed to grow for
an additional 2 h. Cells were harvested from a 500-ml culture by
centrifugation (11,000 × g, 15 min), washed with 250 ml of 10 mM sodium phosphate buffer (pH 7.8), and recentrifuged (11,000 × g, 15 min). The cell pellet was resuspended
in 5 ml of the same buffer. Cells were disrupted by sonication on ice for three 1-min pulses, with 1 min of cooling between pulses, with a
Vibra-Cell probe sonicator at an output setting of 4 and a 50% duty
cycle (Sonics & Materials, Inc., Danbury, Conn.). Cell debris and
insoluble proteins were removed by centrifugation (14,000 × g, 20 min), and the resulting supernatant was stored in small aliquots at
20°C. Total protein concentration of cell extracts was
determined by dye-binding assay (4) with bovine serum
albumin for calibration (Bio-Rad Laboratories, Hercules, Calif.).
Interaction of E. coli cell extracts with
zwittermicin A.
A total of 10 µl of E. coli cell
extract (60 mg of total protein per ml) was incubated with 50 µg of
zwittermicin A made up to a final volume of 20 µl with 10 mM sodium
phosphate (pH 7.8) for 16 h at 28°C. The antimicrobial activity
of zwittermicin A was tested by bioassay on 100MH8.1 plates. To
inactivate protein components of the cell extracts, mixtures were
either heated to 95°C for 15 min or a 10-µl cell extract was
treated with 1 µl of proteinase K (20 mg/ml) (Sigma, St. Louis, Mo.)
at 37°C for 30 min.
Bioassay for activity of zwittermicin A.
Antibacterial
activity of zwittermicin A was tested against the sensitive target
organism E. coli DH5
(Gibco-BRL) in a soft agar overlay
on Mueller-Hinton plates. For bioassays performed on 100MH8.1 plates,
25 µl of an overnight bacterial culture was mixed with 3.0 ml of
100MH8.1 soft agar and plated. For bioassays performed on 10MH8.1
plates, 100 µl of a 10
2 dilution of an overnight
culture was mixed with 3.0 ml of 10MH8.1 soft agar and plated. Reaction
mixtures were spotted on sterile filter disks on top of the soft agar
overlay. Plates were incubated for 18 to 24 h at 28°C, and the
zones of inhibition were measured.
Chemical analysis of zwittermicin A exposed to E. coli cell extracts.
Zwittermicin A exposed to cell extracts
was partially purified by ultrafiltration with an Ultrafree-MC
10,000-Da molecular-mass cutoff column (Millipore Corp., Bedford,
Mass.) by mixing the reaction with 300 µl of water and then
centrifuging it (5,000 × g, 60 min). The filtrate was
dried in a Speed-Vac Concentrator (Savant Instruments, Inc.,
Farmington, N.Y.) and resuspended to a final concentration of 10 µg
of zwittermicin A per ml, and then 30 to 50 µg of zwittermicin A was
analyzed by high-voltage paper electrophoresis (HVPE) (29)
or thin-layer chromatography (TLC). For analysis by TLC, 30 to 50 µg
of zwittermicin A was spotted on silica gel 60 plates (EM Separations
Technology, Darmstadt, Germany) and developed by using a solvent system
consisting of n-butanol, acetic acid, and water (2:1:1, by
volume). HVPE papers were stained with either silver nitrate or
ninhydrin (29). TLC plates were stained similarly with
either silver nitrate or ninhydrin applied by aerosol propellant (Sigma).
Large-scale inactivation and purification of zwittermicin A.
To inactivate large quantities of zwittermicin A, reaction mixtures
were scaled up to include 600 µl of cell extract (60 mg of total
protein per ml) and 3 mg of zwittermicin A in a final volume of 960 µl for 16 h at 28°C. The reaction was divided, and 110 µl of
the reaction was mixed with 290 µl water and spun in a 10,000-Da
molecular-mass cutoff column as described above. Samples were dried in
a Speed-Vac, resuspended in 800 µl of water, and centrifuged to
remove insoluble debris. The soluble portion was passed through a
0.2-µm-pore-size filter and dried. The sample was resuspended in 150 µl of water, and the equivalent of 1 mg of zwittermicin A was loaded
on a Beckman model 125 High-Performance Liquid Chromatograph with a
Beckman Ultrasphere Cyano Bonded-Phase Column (10 mm by 25 cm; Beckman
Instruments, Inc., Fullerton, Calif.). The mobile phase flow rate was 2 ml/min and consisted of 1 mM ammonium acetate for the first 5 min, a 1 to 19 mM gradient of ammonium acetate (pH 6.5) for 40 min, and 19 mM
ammonium acetate (pH 6.5) for 30 min (30). Fractions were
monitored at A218, collected every 2 min, dried
down, and analyzed by HVPE for the presence of modified zwittermicin A. Fractions containing modified zwittermicin were dried and combined for
analysis by nuclear magnetic resonance (NMR).
NMR spectrum determination.
13C NMR data were
acquired with a Varian Unity 400 spectrometer. 1H,
1H-1H RelayH, 1H-13C
heteronuclear multiple quantum correlation (HMQC) and
1H-13C heteronuclear multiple bond correlation
(HMBC) NMR data were collected with a Varian Unity 500 spectrometer.
HMQC and HMBC experiments were run by using pulsed-field gradients. All
experiments were run in D2O (100.0 Atom %D; Aldrich).
1H spectra were referenced at
4.8 by using the residual
partially protonated water present in the sample. 13C
spectra were referenced with dioxane (
67.4) as an internal standard. A high-resolution fast atom bombardment mass spectrum (HRFABMS) was acquired by the University of Illinois (Urbana) Mass
Spectrometry Facility.
Construction of ZmaR overexpression vector.
The ligation
independent cloning cloning kit was used to clone and overexpress
recombinant ZmaR protein. Plasmid pCAL-n-EK (Stratagene) was used to
clone PCR products containing the zmaR coding region with
12- and 13-nucleotide vector-specific sequences introduced at either
end of the coding sequence by PCR. DNA was amplified in 50-µl PCR
reactions, with a final concentration of the following components: 1×
Pfu polymerase reaction buffer (Stratagene), 200 µM
concentrations of each deoxynucleoside triphosphate (Boehringer Mannheim), 0.2 µM concentrations of each primer (primer 11115 [5'-GACGACGACAAGATGATTTATGAATTGGTAAA-3'] and primer
11114 [5'-GGAACAAGACCCGTTCATCTTAAGCTATCTTCAA-3']), 0.2 ng
of plasmid pZMG4 DNA (16), and 1.25 U of Pfu
polymerase (Stratagene). Amplification was performed with a
Thermocycler (Robocycler, Stratagene) as follows: one cycle at 94°C
for 30 s; 20 cycles of 94°C for 45 s, 45°C for 45 s,
and 72°C for 2 min; and a final extension of 72°C for 10 min. PCR
products were purified with a QIAQuick-Spin PCR purification kit
(Qiagen) and single-strand overhangs of 12 and 13 nucleotides were
generated by incubating 50 ng of purified product with 1 U of
Pfu polymerase and 1 mM dATP at 72°C for 10 min. The
prepared insert and 20 ng of pCAL-n-EK vector were allowed to anneal
overnight at room temperature. Mixture was transformed into XL1-Blue
(Stratagene) and plated on LB agar containing 50 mg of ampicillin per
liter; one resulting pCAL-ZmaR clone was sequenced to confirm that no
mutations had been introduced into the zmaR coding region by
PCR amplification. This construct was transformed into E. coli BL21(DE3) (Stratagene) for protein purification.
Interestingly, the pCAL-ZmaR construct conferred zwittermicin A
resistance on E. coli, demonstrating that the recombinant CBP-ZmaR protein retained activity despite the presence of the 4-kDa
calmodulin binding peptide (CBP) affinity tag fused to the N terminus
of ZmaR (data not shown).
Overexpression and purification of recombinant CBP-ZmaR.
Next, 5.0 ml of an overnight culture grown in LB broth with 50 mg of
ampicillin per liter was added to 500 ml of LB-ampicillin in a Fernbach
flask, and the mixture was incubated with shaking at 28°C until an
optical density at 600 nm of 0.6 to 0.8 was reached. IPTG (1 mM) was
added to induce expression of CBP-ZmaR, and the culture was grown at
room temperature for an additional 3 h before cells were
harvested. Cells were harvested by centrifugation and resuspended in 20 ml of CaCl2 binding buffer consisting of 50 mM Tris-HCl (pH
8.0), 300 mM NaCl, and 2 mM CaCl2. Then, 8 mg of lysozyme
was added, and the cells were incubated at 28°C for 30 min.
-Mercaptoethanol (
-ME) was added to a final concentration of 10 mM, and the cells were disrupted by sonication and separated from cell
debris and insoluble proteins as described above. By using the lower
temperatures of 28°C and room temperature, respectively, for cell
growth and induction of CBP-ZmaR expression, nearly 50% of the
CBP-ZmaR remained in the soluble fraction of BL21(DE3) cell lysate,
which was used for affinity purification of CBP-ZmaR. The soluble
fraction was incubated with 10 ml of calmodulin affinity resin
(Stratagene) with mechanical rocking for 16 h at 4°C. The mixture was poured into a 10-ml syringe barrel (Becton Dickinson, Franklin Lakes, N.J.), creating the column used for subsequent purification of CBP-ZmaR. The column was washed with 100 ml of CaCl2 binding buffer (5 to 10 column volumes) containing 10 mM
-ME to remove contaminating proteins, and CBP-ZmaR was eluted with 50 ml of elution buffer containing 2 mM EGTA, 50 mM Tris-HCl, 10 mM
-ME, and 0.05% Triton X-100. Then, 8- to 10-ml fractions were
collected and analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (17) as described previously
(19). We were unable to cleave the 4-kDa affinity tag from
the N terminus of the recombinant CBP-ZmaR protein due to proteolytic
degradation of the protein (9a). However, since the CBP-ZmaR
protein construct conferred resistance on E. coli, it seemed
likely that the protein would still be active if the tag were to remain
on. Next, 20% glycerol (vol/vol) was added to fractions containing
CBP-ZmaR, and aliquots were flash frozen in a dry ice-ethanol bath and
stored at
80°C. The protein concentration was determined by dye
binding as described above (4).
Inactivation of zwittermicin by CBP-ZmaR.
Reaction mixtures
made up to a final volume of 18 µl with 10 mM sodium phosphate buffer
(pH 7.8) contained 4 µg of zwittermicin A and 100 ng of CBP-ZmaR or a
corresponding volume of protein elution buffer containing 20%
glycerol. Cofactors were added to a final concentration of 5 mM acetyl
coenzyme A (acetyl-CoA; sodium salt; Sigma), 4 mM ATP (pH 7.5), or 4 mM
acetyl phosphate (Sigma). Reaction mixtures were incubated at 28°C
for 16 h and assayed for antimicrobial activity by bioassay on
10MH8.1 plates.
Assay for acetyltransferase activity.
Reaction mixtures made
up to a final volume of 20 µl with 10 mM sodium phosphate buffer (pH
7.8) containing 5 µl of either CBP-ZmaR (0.73 mg/ml) or protein
elution buffer with 4 µl of zwittermicin A (1 µg/µl), and 0.1 µl of [1-14C]acetyl-CoA (50 µCi/ml; 50 to 62 mCi/mmol; Amersham Life Science, Inc., Arlington Heights, Ill.) were
incubated at 28°C for 2 h and subsequently dried in a Speed-Vac.
Then, 2 µl of water was added to the sample, and the entire sample
was separated by TLC as described above. The plate was exposed to a
PhosphorImager plate (Molecular Dynamics) for 24 h and analyzed.
Because free acetyl-CoA and acetylated zwittermicin A have similar
Rf values on TLC, in order to achieve the most
interpretable results it was necessary to work under conditions where
acetyl-CoA was limiting to ensure the transfer of all radioactive label
to zwittermicin A. Similar results were obtained under conditions where
acetyl-CoA was present in excess or was limiting.
 |
RESULTS |
zmaR-containing cell extracts inactivate zwittermicin
A.
We previously demonstrated that E. coli DH5
strains carrying zmaR express the ZmaR protein and are
resistant to zwittermicin A (19). To determine whether ZmaR
mediates the inactivation of zwittermicin A, we incubated E. coli DH5
F'IQ cell extracts carrying vector alone (pGEM) or
zmaR (pZMG4) with zwittermicin A and assayed for
antimicrobial activity of the reaction mixture against E. coli DH5
(Fig. 1). The antibiotic
activity of 50 µg of zwittermicin A was abolished when it was mixed
with zmaR-containing cell extracts, but no loss of
antibiotic activity was observed when it was mixed with pGEM-containing
cell extracts. The ability of zmaR-containing cell extracts
to inactivate zwittermicin A was abolished by heating the cell extract
to 95°C or treating it with proteinase K prior to the addition of
zwittermicin A, suggesting dependence on a protein (data not shown).

View larger version (146K):
[in this window]
[in a new window]
|
FIG. 1.
zmaR-containing cell extracts inactivate
zwittermicin A. A zone of inhibition indicates activity of zwittermicin
A against E. coli; the assay was initiated with 50 µg of
zwittermicin A. Zones: 1, zwittermicin A alone; 2, zwittermicin A
incubated with vector-containing (pGEM) cell extract; 3, zwittermicin A
incubated with zmaR-containing (pZMG4) cell extract.
|
|
Inactivated zwittermicin A differs chemically from active
zwittermicin A.
A total of 30 to 50 µg of zwittermicin A that
had been incubated with pGEM- or zmaR-containing cell
extracts and partially purified was analyzed by HVPE and TLC (Table
1). In each of these cases, the
zwittermicin A that had been incubated with the pGEM-containing cell
extract exhibited a different mobility than the zwittermicin A that had
been incubated with the zmaR-containing cell extract. Furthermore, the high-pressure liquid chromatography (HPLC) retention time of zwittermicin A exposed to zmaR-containing cell
extract differed from that of zwittermicin A not exposed to cell
extract (Table 1). These data demonstrate that zwittermicin A
inactivated by zmaR-containing cell extracts differs
chemically from active zwittermicin A, suggesting that it has been
covalently modified.
Structure of modified zwittermicin A.
1H-1H RelayH, 1H-13C
HMQC, and 1H-13C HMBC experiments confirm that
the inactivated zwittermicin skeleton (C-1 to C-15) is identical to
that of native zwittermicin A1 (Fig.
2). 13C chemical shifts
assigned by 1H-13C HMQC confirm that C-3, C-10,
and C-14 are N-substituted carbons, while C-8, C-9, C-11, C-13, and
C-15 are O-substituted carbons as seen in zwittermicin A. Two spin
systems, C-3 to C-4 and C-8 to C-15, are defined by
1H-1H RelayH experiments. The C-1 to C-5
partial structure of the native zwittermicin A skeleton is confirmed by
HMBC correlations from the C-5 carbonyl and C-1 urea to both H-3
methylene protons and an HMBC correlation from the C-5 carbonyl to the
H-4 methine of the C-3 to C-4 spin system. The amide bond that links
C-4 to the second spin system (C-8 to C-15), which completes the native zwittermicin skeleton, is confirmed by an HMBC correlation between the
C-7 carbonyl and H-8 methine proton.
The molecular formula of inactivated zwittermicin A
C
15H
30N
6O
9 (HRFABMS,
m/
z = 439.2149 [MH
+]; calculated,
439.2152) differs from native zwittermicin A
(C
13H
28N
6O
8)
by
C
2H
2O. This two-carbon unit is established as
an acetate by
an HMBC correlation between the additional C-17 (

174.4) carbonyl
carbon and the H-18 (

2.01) methyl singlet observed
in the inactivated
zwittermicin A
13C and
1H
NMR spectra. Deshielding of H-14 (

+0.47

) and shielding of
H-13
(

0.30

) and H-15 (

0.16,

0.10

) define
inactivated
zwittermicin A as the C-14
N-acetylation product
of zwittermicin
A.
N-Acetylation at C-14 is further
confirmed by the presence
of a weak HMBC correlation between the C-17
carbonyl and H-14
methine proton (Table
2).
Zwittermicin A inactivation by recombinant CBP-ZmaR.
Based on
the structure of the modified antibiotic, we postulated that ZmaR is an
acetyltransferase acting directly on zwittermicin A. Furthermore, the
addition of the potential cofactors acetyl-CoA and ATP to
zmaR-containing cell extracts increased the inactivation of
zwittermicin A, as determined by bioassay and TLC; the addition of the
potential cofactors malonyl-CoA, propionyl-CoA, and butyryl-CoA did not
increase the inactivation of zwittermicin A (data not shown). Since the
addition of either acetyl-CoA or ATP to cell extract would have the net
effect of increasing the amount of acetyl-CoA in cell extract, this
suggested that the preferred donor group for the inactivation of
zwittermicin A is an acetyl group. We incubated CBP-ZmaR and
zwittermicin A individually with ATP, acetyl-CoA, and acetyl phosphate
(the latter two cofactors are potential donors of the acetyl group) and
assayed for antimicrobial activity of zwittermicin A by bioassay (Table
3). Protein elution buffer provided a
control treatment to show dependence of the reaction on CBP-ZmaR.
Zwittermicin A that had been incubated with CBP-ZmaR and acetyl-CoA,
but not the other combinations, showed a loss of antimicrobial activity
(Table 3), suggesting that CBP-ZmaR acts
directly on zwittermicin A as an acetyltransferase and requires acetyl-CoA as a cofactor.
Acetyltransferase activity of CBP-ZmaR.
To provide direct
evidence that the inactivation of zwittermicin A by CBP-ZmaR is due to
the transfer of an acetyl group from acetyl-CoA to zwittermicin A, we
incubated CBP-ZmaR with zwittermicin A and radiolabeled acetyl-CoA and
then analyzed the products by TLC (Fig.
3). We observed a distinct shift in both
the mobility and the shape of the radioactive spot only when
zwittermicin A, CBP-ZmaR, and acetyl-CoA were supplied together in a
reaction and not when any of these components were omitted. A TLC plate containing both radioactive acetyltransferase reactions and
HPLC-purified acetylated zwittermicin A as a standard, which was
stained with silver nitrate subsequent to radioactive detection,
verified that the radioactive spot attributed to acetylated
zwittermicin A had the same Rf as the purified
acetylated zwittermicin A (data not shown). Together, these data
demonstrate that zwittermicin A is the substrate of the
acetyltransferase reaction catalyzed by the enzyme CBP-ZmaR and that
acetyl-CoA is the donor group. Therefore, given the lack of homology of
ZmaR with known acetyltransferases, ZmaR may constitute a novel class
of acetyltransferase.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
CBP-ZmaR acetyltransferase reactions. Acetyltransferase
reaction mixtures contained CBP-ZmaR or protein elution buffer,
zwittermicin A, and [1-14C]acetyl-CoA. Samples were
separated by TLC on silica 60 gel plates with
n-butanol-acetic acid-water (2:1:1) as solvent. TLC plate
was visualized on a PhosphorImager. Lanes: 1, free acetyl-CoA; 2, acetyltransferase reaction with zwittermicin A omitted; 3, acetyltransferase reaction with CBP-ZmaR omitted; 4, complete
acetyltransferase reaction; 5, complete acetyltransferase reaction with
one-tenth the amount of CBP-ZmaR. Acetylated zwittermicin A was
identified by comigration with authentic HPLC-purified acetylated
zwittermicin A (not shown).
|
|
 |
DISCUSSION |
We have shown that zmaR, a zwittermicin A resistance
gene from B. cereus UW85, encodes an acetyltransferase that
inactivates zwittermicin A in vitro. E. coli cell extracts
containing zmaR inactivated zwittermicin A by acetylation,
and purified ZmaR protein inactivated zwittermicin A only in the
presence of the cofactor acetyl-CoA. By radiochemical assay we
demonstrated directly that ZmaR is an acetyltransferase. This work is
particularly significant since ZmaR, by its lack of sequence similarity
to proteins of known function, appears to constitute a novel antibiotic
resistance determinant. In this era of increasing antibiotic
resistance, the characterization of new resistance determinants is
vital. Moreover, since the zmaR gene is widespread among
Bacillus spp., which are abundant in soils worldwide, the
possibility of horizontal transfer to target pathogens is great.
Antibiotic resistance via acetylation is common in both
antibiotic-producing organisms (6, 23, 33, 34) and target organisms (14, 20, 25, 28), and acetyltransferases are a
well-studied group of enzymes. Therefore, it is especially surprising that ZmaR does not have amino acid similarity or motifs common to any
known acetyltransferases, as determined by the MOTIFS and PROFILESCAN
programs and by PROCITE (19). Two conserved domains present
in N-acetyltransferases are believed to be important for acetyl-CoA binding (5, 15). Manual alignment of the ZmaR sequence with these motifs revealed that 6 of 24 amino acids in the
consensus amino acid sequence (15) are conserved in the ZmaR
sequence. Recent analysis of a superfamily of diverse
N-acetyltransferases, with representatives drawn from
plants, animals, and prokaryotes, suggests that the sequence of these
motifs may diverge from the previously described consensus sequence
(21). ZmaR contains five of eight highly conserved residues,
but contains very few moderately conserved residues identified in this
analysis (21). Thus, ZmaR may have limited similarity to
other known acetyltransferases in regions believed to interact with
acetyl-CoA. To determine whether the three-dimensional structure of
ZmaR resembled other acetyltransferase enzymes, we subjected ZmaR to a
fold recognition server (9, 34a), since the amino acid
sequence of a protein may not show homology to proteins with which it
shares a three-dimensional (3D) structure. The recent elucidation of
the crystal structure of an aminoglycoside phosphotransferase enzyme
revealed striking similarities in its 3D structure compared to
eukaryotic protein kinases, despite no evidence of sequence homology
(13). However, ZmaR did not show similarity to any proteins,
suggesting that the overall 3D structure of ZmaR may, in fact, be
novel. Alternatively, these results may simply reflect the lack of 3D
structural analysis of acetyltransferase enzymes.
It is interesting that ZmaR shares significant sequence similarity
(24% sequence identity; 43% sequence similarity over 269 amino acids)
with a protein of unknown function deduced from the B. subtilis gene ydfB (16). ydfB is
located in a region of the B. subtilis genome that encodes
many putative antibiotic resistance proteins. It is intriguing that
ZmaR may therefore represent the first of a class of proteins, with
ydfB possibly being another, that acetylate structurally
similar substrates. The range of molecules acetylated by these proteins
may include antibiotics that have not yet been discovered, as well as
known antibiotics of clinical or agricultural importance.
A worldwide survey showed that B. cereus is present in soil
at 105 CFU/g (30a), and 25% of this population
contain zmaR (24, 32), indicating that there are
likely to be 25,000 copies of zmaR in every gram of soil.
Many crops are inoculated with an insecticide-producing strain of
B. thuringiensis, HD-1, that contains zmaR and
produces zwittermicin A (24, 32). Strains of B. cereus are currently being developed for use as biological control
agents to suppress several plant diseases caused by the pathogenic
Phytophthora and Pythium oomycetes (11,
22). Is it possible that zmaR could be transferred to
these target organisms, short-circuiting the ability of B. cereus to control plant disease? It has long been suggested that
antibiotic-producing organisms are the source of the antibiotic
resistance genes found in clinical isolates because the biochemical
mechanisms of antibiotic resistance from antibiotic-producing organisms
and target organisms are similar (2). Moreover, it was
recently shown that some antibiotic preparations are contaminated with
DNA, including antibiotic resistance genes, from the
antibiotic-producing organisms (35). This suggests a source
of antibiotic resistance genes for target human pathogens, which are
conveniently administered simultaneously with the antibiotic. The
prevalence of zmaR in an agricultural setting concomitant
with selection pressure from zwittermicin A may represent an analogous
situation for plant pathogenic oomycetes and other soil microflora.
Further studies of zmaR will contribute to our understanding
of zwittermicin A resistance and may aid in the development of
strategies to reduce the rate of appearance of resistance in target organisms.
 |
ACKNOWLEDGMENTS |
We thank Sandra J. Raffel for purification of the zwittermicin A.
This study made use of the National Magnetic Resonance Facility at
Madison, which is supported by NIH grant RR02301 from the Biomedical
Research Technology Program, National Center for Research Resources.
Equipment in the facility was purchased with funds from the University
of Wisconsin, the NSF Biological Instrumentation Program (grant
DMB-8415048), the NIH Biomedical Research Technology Program (grant
RR02301), the NIH Shared Instrumentation Program (grant RR02781), and
the U.S. Department of Agriculture. We thank Robert Steele for initial
support of this project. This work was also supported by the
University-Industry Research Program and Hatch Project 4038 of the
University of Wisconsin-Madison College of Agricultural and Life Sciences.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Wisconsin, Department of Plant Pathology, 1630 Linden Dr., Madison, WI 53706. Phone: (608) 263-8783. Fax: (608) 262-8643. E-mail:
joh{at}plantpath.wisc.edu.
Present address: Northwestern University Medical School, Chicago,
IL 60611.
 |
REFERENCES |
| 1.
|
Altshchul, S. F.,
W. Gish,
W. Miller,
E. W. Myers, and D. J. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[Medline].
|
| 2.
|
Benveniste, R., and J. Davies.
1973.
Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria.
Proc. Natl. Acad. Sci. USA
70:2276-2280[Abstract/Free Full Text].
|
| 3.
|
Blattner, F. R.,
G. Plunkett III,
C. A. Block,
N. T. Perna,
V. Burland,
M. Riley,
J. Collado-Vides,
J. D. Glasner,
C. K. Rode,
G. F. Mayhew,
J. Gregor,
N. W. Davis,
H. A. Kirkpatrick,
M. A. Goeden,
D. J. Rose,
B. Mau, and Y. Shao.
1997.
The complete genome sequence of Escherichia coli K-12.
Science
277:1453-1462[Abstract/Free Full Text].
|
| 4.
|
Bradford, M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein using the principles of protein-dye binding.
Anal. Biochem.
72:248-254[Medline].
|
| 4a.
| Broderick, N. A., R. M. Goodman, K. F. Raffa, and J. Handelsman. Synergy between zwittermicin A and Bacillus
thuringiensis subsp. kurstaki against gypsy moth.
Environ. Entomol., in press.
|
| 5.
|
Coon, S. L.,
P. H. Roseboom,
R. Baler,
J. L. Weller,
M. A. A. Namboodiri,
E. V. Koonin, and D. C. Klein.
1995.
Pineal serotonin N-acetyltransferase: expression cloning and molecular analysis.
Science
270:1681-1683[Abstract/Free Full Text].
|
| 6.
|
Cundliffe, E.
1989.
How antibiotic-producing organisms avoid suicide.
Annu. Rev. Microbiol.
43:207-233[Medline].
|
| 7.
|
Davies, J.
1994.
Inactivation of antibiotics and the dissemination of resistance genes.
Science
264:375-382[Abstract/Free Full Text].
|
| 8.
|
Felske, A.,
A. Wolterink,
R. Van Lis, and A. D. L. Akkermans.
1998.
Phylogeny of the main bacterial 16S rRNA sequences in Drentse A grassland soils (The Netherlands).
Appl. Environ. Microbiol.
64:871-879[Abstract/Free Full Text].
|
| 9.
|
Fischer, D., and D. Eisenberg.
1997.
Assigning folds to the proteins encoded by the genome of Mycoplasma genitalium.
Proc. Natl. Acad. Sci. USA
94:11929-11934[Abstract/Free Full Text].
|
| 9a.
| Gross, J. A., et al. Unpublished data.
|
| 10.
|
Hanahan, D.
1983.
Studies on transformation of Escherichia coli with plasmids.
J. Mol. Biol.
166:557-580[Medline].
|
| 11.
|
Handelsman, J.,
S. Raffel,
E. H. Mester,
L. Wunderlich, and C. R. Grau.
1990.
Biological control of damping-off of alfalfa seedlings with Bacillus cereus UW85.
Appl. Environ. Microbiol.
56:713-718[Abstract/Free Full Text].
|
| 12.
|
He, H.,
L. A. Silo-Suh,
J. Clardy, and J. Handelsman.
1994.
Zwittermicin A, an antifungal and plant protection agent from Bacillus cereus.
Tetrahedron Lett.
35:2499-2502.
|
| 13.
|
Hon, W.-C.,
G. A. McKay,
P. R. Thompson,
R. M. Sweet,
D. S. C. Yang,
G. D. Wright, and A. M. Berghuis.
1997.
Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases.
Cell
89:887-895[Medline].
|
| 14.
|
Hotta, K.,
C.-B. Zhu,
T. Ogata,
A. Sunada,
J. Ishikawa, and S. Mizuno.
1996.
Enzymatic 2'-N-acetylation of arbekacin and antibiotic activity of its product.
J. Antibiot.
49:458-464[Medline].
|
| 15.
|
Kimberly, L. L.,
A. Berkey, and R. A. Casero, Jr.
1996.
RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N1 acetyltransferase.
J. Biol. Chem.
271:18920-18924[Abstract/Free Full Text].
|
| 16.
|
Kunst, F.,
N. Ogasawara,
I. Moszer,
A. M. Albertini,
G. Alloni,
V. Azevedo,
M. G. Bertero,
P. Bessieres,
A. Bolotin,
S. Borchert,
R. Borriss, et al.
1997.
The complete genome sequence of the gram-positive bacterium Bacillus subtilis.
Nature
390:249-256[Medline].
|
| 17.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[Medline].
|
| 18.
| Manker, D. C., W. D. Lidster, R. L. Starnes, and S. C. MacIntosh. May 1994. Potentiator of
Bacillus pesticidal activity. Patent cooperation treaty, WO
94/09630.
|
| 19.
|
Milner, J. L.,
E. A. Stohl, and J. Handelsman.
1996.
Zwittermicin A resistance gene from Bacillus cereus.
J. Bacteriol.
178:4266-4272[Abstract/Free Full Text].
|
| 20.
|
Murray, I. A., and W. V. Shaw.
1997.
O-Acetyltransferases for chloramphenicol and other natural products.
Antimicrob. Agents Chemother.
41:1-6[Medline].
|
| 21.
|
Neuwald, A. F., and D. Landsman.
1997.
GCN5-related histone-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein.
Trends Biochem. Sci.
22:154-155[Medline].
|
| 22.
|
Osburn, R. M.,
J. L. Milner,
E. S. Oplinger,
R. S. Smith, and J. Handelsman.
1995.
Effect of Bacillus cereus UW85 on the yield of soybean at two field sites in Wisconsin.
Plant Dis.
79:551-556.
|
| 23.
|
Perez-Gonzalez, J. A.,
M. Lopez-Cabrera,
J. M. Pardo, and A. Jimenez.
1989.
Biochemical characterization of two cloned resistance determinants encoding a paromycin acetyltransferase and a paromycin phosphotransferase from Streptomyces rimosus forma paromomycinus.
J. Bacteriol.
171:329-334[Abstract/Free Full Text].
|
| 24.
|
Raffel, S. J.,
E. V. Stabb,
J. L. Milner, and J. Handelsman.
1996.
Genotypic and phenotypic analysis of zwittermicin A-producing strains of Bacillus cereus.
Microbiology
142:3425-3436[Abstract/Free Full Text].
|
| 25.
|
Rather, P. N.,
E. Orosz,
K. J. Shaw,
R. Hare, and G. Miller.
1993.
Characterization and transcriptional regulation of the 2'-N-acetyltransferase gene from Providencia stuartii.
J. Bacteriol.
175:6492-6498[Abstract/Free Full Text].
|
| 26.
|
Salyers, A. A., and N. B. Shoemaker.
1996.
Resistance gene transfer in anaerobes: new insights, new problems.
Clin. Infect. Dis.
23(Suppl. 1):36-43.
|
| 27.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 28.
|
Shaw, K. J.,
P. N. Rather,
R. S. Hare, and G. H. Miller.
1993.
Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes.
Microbiol. Rev.
57:138-163[Abstract/Free Full Text].
|
| 29.
|
Silo-Suh, L. A.,
B. J. Lethbridge,
S. J. Raffel,
H. He,
J. Clardy, and J. Handelsman.
1994.
Biological activities of two fungistatic antibiotics produced by Bacillus cereus UW85.
Appl. Environ. Microbiol.
60:2023-2030[Abstract/Free Full Text].
|
| 30.
|
Silo-Suh, L. A.,
E. V. Stabb,
S. J. Raffel, and J. Handelsman.
1998.
Target range of zwittermicin A, an aminopolyol antibiotic from Bacillus cereus.
Curr. Microbiol.
37:6-11[Medline].
|
| 30a.
| Stabb, E. V., et al. Unpublished data.
|
| 31.
|
Stabb, E. V., and J. Handelsman.
1998.
Genetic analysis of zwittermicin A resistance in Escherichia coli: effects on membrane potential and RNA polymerase.
Mol. Microbiol.
27:311-322[Medline].
|
| 32.
|
Stabb, E. V.,
L. M. Jacobson, and J. Handelsman.
1994.
Zwittermicin A-producing strains of Bacillus cereus from diverse soils.
Appl. Environ. Microbiol.
60:4404-4412[Abstract/Free Full Text].
|
| 33.
|
Sugiyama, M.,
T. Kumagai,
M. Shionoya,
E. Kimura, and J. E. Davies.
1994.
Inactivation of bleomycin by an N-acetyltransferase in the bleomycin-producing strain Streptomyces verticillus.
FEMS Microbiol. Lett.
121:81-86[Medline].
|
| 34.
|
Sugiyama, M.,
S.-Y. Paik, and R. Nomi.
1985.
Mechanism of self-protection in a puromycin-producing micro-organism.
J. Gen. Microbiol.
131:1999-2005[Abstract/Free Full Text].
|
| 34a.
| UCLA-DOE Fold Recognition Server. [Online.]
http://fold.doe-mbi.ucla.edu/. [27 July 1999, last date
accessed.]
|
| 35.
|
Webb, V., and J. Davies.
1993.
Antibiotic preparations contain DNA: a source of drug resistance genes?
Antimicrob. Agents Chemother.
37:2379-2384[Abstract/Free Full Text].
|
| 36.
|
Whitman, W. B.,
D. C. Coleman, and W. J. Wiebe.
1998.
Prokaryotes: the unseen majority.
Proc. Natl. Acad. Sci. USA
95:6578-6583[Abstract/Free Full Text].
|
Journal of Bacteriology, September 1999, p. 5455-5460, Vol. 181, No. 17
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kevany, B. M., Rasko, D. A., Thomas, M. G.
(2009). Characterization of the Complete Zwittermicin A Biosynthesis Gene Cluster from Bacillus cereus. Appl. Environ. Microbiol.
75: 1144-1155
[Abstract]
[Full Text]